Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Sollie-Zetlmayer Hege Elisabeth 2. Date of Event Requiring Statement (Month/Day/Year) 07/28/2026 3. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT] (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) WARREN, NJ 07059 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 46,526(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	10/22/2030	Common Stock	14,000	$51.96	D
Stock Option (Right to Buy)	(2)	01/05/2031	Common Stock	33,250	$66.49	D
Stock Option (Right to Buy)	(2)	01/06/2032	Common Stock	17,875	$38.1	D
Stock Option (Right to Buy)	(3)	01/04/2033	Common Stock	11,250	$39.42	D
Stock Option (Right to Buy)	(4)	02/14/2034	Common Stock	25,000	$25.69	D
Stock Option (Right to Buy)	(5)	01/02/2035	Common Stock	25,000	$46.54	D
Stock Option (Right to Buy)	(6)	01/01/2036	Common Stock	27,500	$76.74	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Sollie-Zetlmayer Hege Elisabeth C/O PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE WARREN, NJ 07059	X

Signatures

/s/ Avraham S. Adler, Attorney-in-Fact		07/30/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes (1) 2,250 unvested Restricted Stock Units ("RSUs") from an award of 9,000 RSUs granted on January 5, 2023, which vests in four equal installments over four years, commencing on January 5, 2024; (2) 5,000 unvested RSUs from an award of 10,000 RSUs granted on February 15, 2024, which vests in four equal installments over four years, commencing on February 15, 2025; (3) 7,500 unvested RSUs from an award of 10,000 RSUs granted on January 3, 2025, which vests in four equal installments over four years, commencing on January 3, 2026; and (4) 11,000 unvested RSUs from an award of 11,000 RSUs granted on January 2, 2026, which vests in four equal installments over four years, commencing on January 2, 2027.
(2)	Currently exercisable.
(3)	This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
(4)	This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
(5)	This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
(6)	This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.